United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - amitriptyline hydrochloride - oral tablet - 10mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

arrow generics ltd - amitriptyline hydrochloride - oral tablet - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

thame laboratories ltd - amitriptyline hydrochloride - oral solution - 2mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

thame laboratories ltd - amitriptyline hydrochloride - oral solution - 5mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

thame laboratories ltd - amitriptyline hydrochloride - oral solution - 10mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

wockhardt uk ltd - amitriptyline hydrochloride - oral solution - 2mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - amitriptyline hydrochloride - oral tablet - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol laboratories ltd - amitriptyline hydrochloride - oral tablet - 50mg

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - mitozantrone hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - isotretinoin, quantity: 20 mg - capsule, soft - excipient ingredients: yellow beeswax; hydrogenated soya oil; soya oil; gelatin; glycerol; titanium dioxide; partially hydrogenated soya oil; iron oxide red; maize starch; sorbitol; mannitol; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - roaccutane is indicated for the treatment of severe cystic acne, and a single course of therapy has been shown to result in complete and prolonged remission of disease in many patients. if a second course of therapy is needed, it should not be initiated until at least eight weeks after completion of the first course, since experience has shown that patients may continue to improve while off drug. because of significant adverse effects associated with its use, roaccutane should be reserved for patients with severe cystic acne who are unresponsive to conventional therapy, including systemic antibiotics.